NCT02640586 is a NA clinical trial of three MR examination in Rectal Neoplasms, sponsored by Sun Ying-Shi.

Who is sponsoring NCT02640586?

NCT02640586 is sponsored by Sun Ying-Shi.

What drugs are being tested in NCT02640586?

Interventions in NCT02640586: three MR examination.

What condition does NCT02640586 study?

NCT02640586 studies Rectal Neoplasms.

Is NCT02640586 still recruiting?

NCT02640586 is currently status unknown. Last updated 22 June 2023.

Last reviewed 2023-06-22 · How we verify

NCT02640586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI

Status unknown NA Last updated 22 June 2023

What this trial tests

NA trial testing three MR examination in Rectal Neoplasms in 1,614 participants. Status unknown.

Timeline

10 January 2016

Primary endpoint
17 July 2020

31 December 2023

Quick facts

Lead sponsor	Sun Ying-Shi
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	1,614
Start date	10 January 2016
Primary completion	17 July 2020
Estimated completion	31 December 2023
Sites	11 locations across China

Drugs / interventions tested

three MR examination

Conditions studied

Rectal Neoplasms — all drugs for Rectal Neoplasms →

Sponsor

Sun Ying-Shi

Who can join

18 and older, any sex, with Rectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate if MRI scans performed after neoadjuvant radiotherapy can predict the therapeutic response of rectal cancer following preoperative chemo-radiotherapy. This will help doctors to better tailor treatments for rectal cancer in the future.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Landscape of Biomarkers and Pathologic Response in Rectal Cancer: Where We Stand?
Ocanto A, Teja M, Amorelli F, Couñago F, et al · · 2024 · cited 5× · PMID 39682232 · DOI 10.3390/cancers16234047

Verify or expand the search:

Other recruiting trials for Rectal Neoplasms

Currently open trials in the same condition.

NCT07522294 — Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision · NA · active not recruiting
NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting
NCT06442215 — Selection of Surgical Technique in Rectal Cancer · recruiting
NCT06017583 — Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT05943444 — Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer · NA · recruiting

Other Sun Ying-Shi trials

Trials by the same sponsor.

NCT03238885 — Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02640586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Ying-Shi
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02640586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing